Peptides by condition · Weight, blood sugar, liver and gut

Peptides studied for type 2 diabetes

Checked against our study pages and the FDA labelsPublished by PepVault

Our library holds 44 study pages on type 2 diabetes: 41 in people (39 of them meta-analyses or randomized trials), and 3 in animals. They studied 19 compounds, with this many study pages each: Retatrutide 5, Dulaglutide 4, Semaglutide 4, Tirzepatide 4, Ecnoglutide 4, Exenatide 3, Semaglutide (oral) 2, Orforglipron 2, CagriSema 2, Mazdutide 2, Amycretin 2, Pramlintide 2, Liraglutide 1, Efinopegdutide 1, Cagrilintide 1, Tesamorelin 1, GHRP-6 1, MOTS-c 2 and NSI-189 1.

What the research on type 2 diabetes looks like

Type 2 diabetes is a long-term condition in which the body stops responding well to insulin and blood sugar runs high. Peptide research on it is led by the GLP-1 drugs and their newer two- and three-hormone relatives, tested against placebo, insulin and each other; several of these drugs began as diabetes medicines.

The main number in a diabetes trial is HbA1c, a blood test that reflects average blood sugar over the past few months. Larger trials also count heart attacks, strokes and kidney decline, because those are what diabetes does over the years.

Check what a drug was compared with: a placebo, a lower dose or another diabetes drug. A study in diabetic rats or mice shows a mechanism, not what a person’s blood sugar will do.

Our study pages on type 2 diabetes by design: Trials in people 39, Other in people 2, Animals 3, Cells 0, of 44.Trials in people39Other in people2Animals3Cells0
How many of the 44 study pages on this condition reach each design, strongest at the top: meta-analyses and randomized trials in people, other studies in people, animals, cells.
A smiling woman in a dark training top in her kitchen, holding a glass of water

Model. Individual results vary.

PepVault for iPhone

Track your own progress in PepVault

Doses, vials, weight and side effects in one log.

Download on the App Store

7 days free on the yearly plan for new subscribers.

The 44 studies, by compound

Grouped by the compound each study is filed under, and within each, strongest design first. Each line gives the design, who was studied, how many and the year, before the finding.

  1. Retatrutide

    5 in people

    For type 2 diabetes, 5 of our study pages are filed under Retatrutide: 4 randomized trials and 1 clinical trial in people. The largest in people enrolled 537 people and was published in 2026. They were published from 2022 to 2026, in Lancet, Diabetes Obes Metab, Lancet Diabetes Endocrinol and Kidney Int Rep.

    Retatrutide has no FDA-approved product: Drugs@FDA lists no application for it, and FDA writes that it is not a component of any FDA-approved drug.

  2. Dulaglutide

    4 in people

    For type 2 diabetes, 4 of our study pages are filed under Dulaglutide: 4 randomized trials in people. The largest in people enrolled 9,901 people and was published in 2019. They were published from 2018 to 2025, in Lancet, Lancet Diabetes Endocrinol and Ann Intern Med.

    FDA-approved, with a use tied to type 2 diabetes on its label: Trulicity (injection) for blood sugar control in type 2 diabetes (adults and children 10 and older), and lowering heart risk in adults with type 2 diabetes and heart disease or several heart risk factors.

  3. Semaglutide

    4 in people

    For type 2 diabetes, 4 of our study pages are filed under Semaglutide: 4 randomized trials in people. The largest in people enrolled 3,533 people and was published in 2024. They were published from 2016 to 2026, in N Engl J Med and Lancet.

    FDA-approved, with a use tied to type 2 diabetes on its label: Ozempic (injection) for blood sugar control in adults with type 2 diabetes, and lowering the risk of heart attack, stroke and kidney decline in those with heart or kidney disease; Rybelsus (tablet) for blood sugar control in adults with type 2 diabetes, and lowering the risk of heart attack and stroke in those at high risk; Ozempic (tablet) for blood sugar control in adults with type 2 diabetes, and lowering the risk of heart attack and stroke in those at high risk (the same label as Rybelsus). Under Wegovy it is approved for other uses.

  4. Tirzepatide

    4 in people

    For type 2 diabetes, 4 of our study pages are filed under Tirzepatide: 4 randomized trials in people. The largest in people enrolled 1,879 people and was published in 2021. They were published from 2021 to 2023, in N Engl J Med, JAMA and Lancet.

    FDA-approved, with a use tied to type 2 diabetes on its label: Mounjaro (injection) for blood sugar control in type 2 diabetes (adults and children 10 and older), and lowering heart risk in adults with type 2 diabetes. Under Zepbound it is approved for other uses.

  5. Ecnoglutide

    4 in people

    For type 2 diabetes, 4 of our study pages are filed under Ecnoglutide: 1 meta-analysis and 3 randomized trials in people. The largest in people pooled 1,643 people and was published in 2026. They were published from 2024 to 2026, in Endocrinol Diabetes Metab, Lancet Diabetes Endocrinol and Nat Commun.

    Ecnoglutide has no FDA-approved product: Drugs@FDA lists no application for it.

  6. Exenatide

    3 in people

    For type 2 diabetes, 3 of our study pages are filed under Exenatide: 3 randomized trials in people. The largest in people enrolled 14,752 people and was published in 2017. They were published from 2017 to 2021, in N Engl J Med, Diabetes Care and Diabetes Obes Metab.

    FDA-approved, with a use tied to type 2 diabetes on its label: Byetta (injection) for blood sugar control, with diet and exercise, in adults with type 2 diabetes.

  7. For type 2 diabetes, 2 of our study pages are filed under Semaglutide (oral): 2 randomized trials in people. The largest in people enrolled 9,650 people and was published in 2025. They were published from 2019 to 2025, in N Engl J Med.

    FDA-approved, with a use tied to type 2 diabetes on its label: Rybelsus (tablet) for blood sugar control in adults with type 2 diabetes, and lowering the risk of heart attack and stroke in those at high risk; Ozempic (tablet) for blood sugar control in adults with type 2 diabetes, and lowering the risk of heart attack and stroke in those at high risk (the same label as Rybelsus). Under Wegovy it is approved for other uses.

  8. Orforglipron

    2 in people

    For type 2 diabetes, 2 of our study pages are filed under Orforglipron: 2 randomized trials in people. The largest in people enrolled 2,749 people and was published in 2026. All were published in 2026, in Lancet.

    FDA-approved for other uses, not for type 2 diabetes: Foundayo (tablet) for weight loss and keeping it off, in adults with obesity or with excess weight and a weight-related condition.

  9. CagriSema

    2 in people

    For type 2 diabetes, 2 of our study pages are filed under CagriSema: 2 randomized trials in people. The largest in people enrolled 1,206 people and was published in 2025. They were published from 2025 to 2026, in N Engl J Med and Lancet.

    CagriSema, cagrilintide combined with semaglutide, has no FDA-approved product: Drugs@FDA lists no application with cagrilintide in it. Semaglutide on its own is approved (Ozempic, Wegovy).

  10. Mazdutide

    2 in people

    For type 2 diabetes, 2 of our study pages are filed under Mazdutide: 2 randomized trials in people. The largest in people enrolled 731 people and was published in 2026. All were published in 2026, in Nature.

    Mazdutide has no FDA-approved product: Drugs@FDA lists no application for it. FDA writes that it has warned companies that illegally sold unapproved drugs containing mazdutide, among others, labeled “for research purposes”.

  11. Amycretin

    2 in people

    For type 2 diabetes, 2 of our study pages are filed under Amycretin: 2 randomized trials in people. The largest in people enrolled 262 people and was published in 2026. All were published in 2026, in Lancet.

    Amycretin has no FDA-approved product: Drugs@FDA lists no application for it.

  12. Pramlintide

    2 in people

    For type 2 diabetes, 2 of our study pages are filed under Pramlintide: 1 meta-analysis and 1 randomized trial in people. The largest in people enrolled 24 people and was published in 2002. They were published from 2002 to 2003, in Diabetes Obes Metab and Horm Metab Res.

    FDA-approved, with a use tied to type 2 diabetes on its label: Symlin for adding to mealtime insulin in type 1 or type 2 diabetes when insulin alone has not reached the blood sugar goal.

  13. Liraglutide

    1 in people

    For type 2 diabetes, 1 of our study pages is filed under Liraglutide: 1 randomized trial in people. It enrolled 9,340 people and was published in 2016, in N Engl J Med.

    FDA-approved, with a use tied to type 2 diabetes on its label: Victoza (injection) for blood sugar control in type 2 diabetes (adults and children 10 and older), and lowering heart risk in adults with type 2 diabetes and heart disease. Under Saxenda it is approved for other uses.

  14. Efinopegdutide

    1 in people

    For type 2 diabetes, 1 of our study pages is filed under Efinopegdutide: 1 randomized trial in people. It enrolled 195 people and was published in 2021, in Clin Obes.

    Efinopegdutide has no FDA-approved product: Drugs@FDA lists no application for it.

  15. Cagrilintide

    1 in people

    For type 2 diabetes, 1 of our study pages is filed under Cagrilintide: 1 randomized trial in people. It enrolled 92 people and was published in 2023, in Lancet.

    Cagrilintide has no FDA-approved product: Drugs@FDA lists no application for it, and FDA writes that it is not a component of any FDA-approved drug.

  16. Tesamorelin

    1 in people

    For type 2 diabetes, 1 of our study pages is filed under Tesamorelin: 1 randomized trial in people. It enrolled 53 people and was published in 2017, in PLoS One.

    FDA-approved for other uses, not for type 2 diabetes: Egrifta (injection) for reducing excess belly fat in adults with HIV and lipodystrophy (its label says it is not for weight loss).

  17. GHRP-6

    1 in people

    For type 2 diabetes, 1 of our study pages is filed under GHRP-6: 1 clinical trial in people. It enrolled 12 people and was published in 2004, in Diabetes Res Clin Pract.

    GHRP-6 has no FDA-approved product: Drugs@FDA lists no application for it.

  18. MOTS-c

    2 in animals

    For type 2 diabetes, 2 of our study pages are filed under MOTS-c: 2 animal studies (mice and rats). None of them is in people. All were published in 2025, in Exp Mol Med and Front Physiol.

    MOTS-c has no FDA-approved product: Drugs@FDA lists no application for it.

  19. NSI-189

    1 in animals

    For type 2 diabetes, 1 of our study pages is filed under NSI-189: 1 animal study (rats). It was published in 2022, in J Diabetes Res.

    NSI-189 has no FDA-approved product: Drugs@FDA lists no application for it.

Side by side

For the 19 compounds on this page: studies in people, studies in animals or cells, the size of the largest study in people, and the FDA status from the labels our status pages read (a dash where they hold no record).

CompoundIn peopleAnimals or cellsLargest in peopleFDA
Retatrutide50537Not approved
Dulaglutide409,901Approved, a use tied to it
Semaglutide403,533Approved, a use tied to it
Tirzepatide401,879Approved, a use tied to it
Ecnoglutide401,643Not approved
Exenatide3014,752Approved, a use tied to it
Semaglutide (oral)209,650Approved, a use tied to it
Orforglipron202,749Approved for other uses
CagriSema201,206Not approved
Mazdutide20731Not approved
Amycretin20262Not approved
Pramlintide2024Approved, a use tied to it
Liraglutide109,340Approved, a use tied to it
Efinopegdutide10195Not approved
Cagrilintide1092Not approved
Tesamorelin1053Approved for other uses
GHRP-61012Not approved
MOTS-c02—Not approved
NSI-18901—Not approved

What the studies did not show

Each study page names its own limits. These are the questions still open, in the study pages’ words.

This page is a reading of published studies, not medical advice. A diagnosis, and what to do about it, is a conversation with a clinician.

Questions

Which peptides have been studied for type 2 diabetes?

Our 44 study pages on type 2 diabetes are filed under 19 compounds, with this many each: Retatrutide 5, Dulaglutide 4, Semaglutide 4, Tirzepatide 4, Ecnoglutide 4, Exenatide 3, Semaglutide (oral) 2, Orforglipron 2, CagriSema 2, Mazdutide 2, Amycretin 2, Pramlintide 2, Liraglutide 1, Efinopegdutide 1, Cagrilintide 1, Tesamorelin 1, GHRP-6 1, MOTS-c 2 and NSI-189 1. Retatrutide has the most.

Have any been tested in people with type 2 diabetes?

Yes: 41 of the 44 were in people, 39 of them meta-analyses or randomized trials (Retatrutide, Dulaglutide, Semaglutide, Tirzepatide, Ecnoglutide, Exenatide, Semaglutide (oral), Orforglipron, CagriSema, Mazdutide, Amycretin, Pramlintide, Liraglutide, Efinopegdutide, Cagrilintide and Tesamorelin). The largest enrolled 14,752 people: “Exenatide: no significant drop in heart events vs placebo in EXSCEL” (2017).

Is any peptide FDA-approved for type 2 diabetes?

Yes, with a use tied to type 2 diabetes on their FDA labels: Dulaglutide as Trulicity; Semaglutide as Ozempic and Rybelsus; Tirzepatide as Mounjaro; Exenatide as Byetta; Semaglutide (oral) as Rybelsus and Ozempic; Pramlintide as Symlin; Liraglutide as Victoza. 12 other compounds here with an FDA record have no use tied to it.

How large were the studies in people on type 2 diabetes?

Of the 41 in people, 39 give their size on our pages: 16 had 1,000 people or more, 17 had 100 to 999 and 6 had fewer than 100. The largest, a randomized trial from 2017, enrolled 14,752.

What did the animal and cell studies on type 2 diabetes use?

3 animal studies (mice and rats), filed under MOTS-c and NSI-189. A result in animals or cells shows what to test next, not what happens in a person.

What is the newest study on type 2 diabetes here?

Of our study pages on type 2 diabetes, the newest is “Ecnoglutide lowered HbA1c and weight in type 2 diabetes: meta-analysis”, a meta-analysis in people published in 2026.

How this page was built

A study page is listed here only where we read its question, design and finding and the study was about this condition: its subjects had the condition, or were an animal or cell model of it, and the study gave them the compound. A study that only mentions the condition is not listed.

Studies are grouped by the compound each is filed under and ordered by design: meta-analyses and randomized trials in people first, then other studies in people, then animals, then cells, and within a group by size and then by year. The FDA status comes from the labels our legal-status and brand pages read.

Track it in the app

PepVault for iPhone

Track your own progress in PepVault

Doses, vials, weight and side effects in one log.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo